Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Drug analysis

Drug analysis


  • Sort by Default
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Votrient

    Read More

    Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical studies have shown the role of PDGF in modulating angiogenesis

    March 6, 2019
    Find out more
  • Afinitor

    Read More

    Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.

    March 6, 2019
    Find out more
  • Sutent

    Read More

    Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and FLT3.

    March 6, 2019
    Find out more
  • abexinostat

    Read More

    Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.

    March 6, 2019
    Find out more
  • Torisel

    Read More

    Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

    March 6, 2019
    Find out more
  • Finerenone

    Read More

    Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of the receptor.

    February 27, 2019
    Find out more
  • Farxiga

    Read More

    Farxiga (dapagliflozin; AstraZeneca) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.

    February 27, 2019
    Find out more
  • Jardiance

    Read More

    Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor originally developed by Boehringer Ingelheim for the treatment of type 2 diabetes.

    February 27, 2019
    Find out more
  • Invokana

    Read More

    Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class.

    February 27, 2019
    Find out more
  • INCB050465

    Read More

    INCB050465 (Incyte) is an oral phosphoinositide 3-kinase (PI3K) delta-specific inhibitor. The PI3K pathway has been shown to be highly active in a subset of follicular lymphoma (FL), promoting cell proliferation and survival. INCB050465 inhibits the PI3K-delta isoform with a 20,000-fold selectivity over other PI3K isoforms.

    February 10, 2019
    Find out more
  • Venclexta_report

    Venclexta

    Read More

    Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins.

    January 31, 2019
    Find out more
  • arzerra report

    Arzerra

    Read More

    Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.

    January 31, 2019
    Find out more
  • Calquence

    Read More

    Calquence (acalabrutinib; AstraZeneca/Acerta) is a novel, orally available, second-generation Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Inhibition of the BTK protein prevents the activation of the B-cell antigen receptor signaling pathway, which blocks both B-cell activation and BTK-mediated activation of downstream survival pathways.

    January 31, 2019
    Find out more
  • Copiktra

    Read More

    Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme.

    January 31, 2019
    Find out more
  • Zanubrutinib

    Read More

    Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson & Johnson). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.

    January 31, 2019
    Find out more
  • Betalutin

    Read More

    Betalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in B cells and B-cell lymphomas.

    January 31, 2019
    Find out more
  • Aliqopa

    Read More

    Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial for normal B-cell development, and is subverted by follicular lymphoma (FL) to promote survival and growth.

    January 31, 2019
    Find out more
  • Gazyva

    Read More

    Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.

    January 31, 2019
    Find out more
  • Rituxan

    Read More

    Rituxan (rituximab; Roche/Biogen/Chugai/Zenyaku Kogyo) is a chimeric monoclonal antibody that binds to the cluster of differentiation (CD)20 antigen, which regulates cell cycle initiation and may function as a calcium ion channel. CD20 is not found on normal plasma cells or normal tissue, but is expressed on over 90% of B-cell non-Hodgkin’s lymphomas (NHLs).

    January 31, 2019
    Find out more
  • Zydelig

    Read More

    Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in decreased phosphorylation Akt and other downstream effectors, an increase in poly (ADP-ribose) polymerase and caspase cleavage, and an induction of apoptosis.

    January 31, 2019
    Find out more
  • imbruvica report

    Imbruvica

    Read More

    Imbruvica is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.

    January 31, 2019
    Find out more
  • Ublituximab

    Read More

    Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.

    January 31, 2019
    Find out more
  • Treanda/Bendeka

    Read More

    Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.

    January 31, 2019
    Find out more
  • Kymriah

    Read More

    Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment that binds CD19 and is linked to intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.

    January 31, 2019
    Find out more
  • Revlimid

    Read More

    Revlimid (lenalidomide; Celgene) is an oral thalidomide analog with antineoplastic, immunomodulatory, and anti-angiogenic properties.

    January 30, 2019
    Find out more
  • Zevalin

    Read More

    Zevalin (ibritumomab tiuxetan; Acrotech Biopharma/Mundipharma) is an intravenous radioactive agent consisting of the murine monoclonal antibody (MAb) ibritumomab, which is covalently linked to the chelator tiuxetan.

    January 30, 2019
    Find out more
  • lisocabtagene maraleucel

    Read More

    Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market following the launches of approved CAR-T drugs Kymriah (tisagenlecleucel; Novartis) and Yescarta (axicabtagene ciloleucel; Gilead).

    January 30, 2019
    Find out more
  • umbralisib

    Read More

    Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.

    January 30, 2019
    Find out more
  • Yescarta

    Read More

    Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.

    January 30, 2019
    Find out more
  • MT-2271

    Read More

    MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs.

    January 14, 2019
    Find out more
  • Flublok

    Read More

    Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • Fluzone High-Dose

    Read More

    Fluzone HD (inactivated split virion; Sanofi Pasteur) is an inactivated influenza vaccine that contains antigens from two A strains and one B strain specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • Flucelvax QIV

    Read More

    Flucelvax is an inactivated subunit cell-based QIV that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • FluMist QIV

    Read More

    FluMist QIV (AstraZeneca/Daiichi Sankyo) is a quadrivalent live-attenuated influenza vaccine containing antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • Fluad QIV

    Read More

    Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.

    January 10, 2019
    Find out more
  • GSK-3

    Read More

    GSK-3 is a 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine, which also includes the conserved, unconjugated pneumococcal proteins dPly and PhtD.

    December 21, 2018
    Find out more
  • v114 report

    V114

    Read More

    Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.

    December 21, 2018
    Find out more
  • Prevnar 13

    Read More

    Prevnar 13 is Pfizer’s follow-on vaccine to Prevnar 7, which was the first pneumococcal conjugate vaccine licensed in the US.

    December 21, 2018
    Find out more
  • Synflorix

    Read More

    Synflorix (GlaxoSmithKline/Japan Vaccine) is a 10-valent pneumococcal conjugate vaccine active against Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F.

    December 21, 2018
    Find out more
  • Pneumovax 23

    Read More

    Pneumovax 23 is a 23-valent polysaccharide vaccine containing 23 purified capsular antigens of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F.

    December 21, 2018
    Find out more
  • PF-06482077

    Read More

    Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.

    December 21, 2018
    Find out more
  • evinacumab

    Evinacumab

    Read More

    Evinacumab (Regeneron) is a monoclonal antibody (MAb) that inhibits angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is secreted naturally by the liver and acts as a partial inhibitor of lipoprotein lipase and endothelial lipase.

    November 20, 2018
    Find out more
  • espanova

    Epanova

    Read More

    Epanova (omefas; AstraZeneca) is an omega-3 fatty acid drug developed for the treatment of severe hypertriglyceridemia. It contains a novel free fatty acid formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

    November 20, 2018
    Find out more
  • ralinepag

    Read More

    Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, which also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.

    October 29, 2018
    Find out more
  • esuberaprost

    Read More

    Esuberaprost (United Therapeutics) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor. PGI2 agonists are potent vasodilators and platelet aggregation inhibitors, and also help relax smooth muscle cells by counteracting the effect of vasoconstrictive mediators.

    October 29, 2018
    Find out more
Page 3 of 14
Page 3 of 14‹12345›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top